---
layout: post
title: "Quantitative Brain Amyloid Positron Emission Tomography Imaging in Patients With Alzheimer's Disease; Public Workshop; Request for Comments"
date: 2026-02-05 19:01:18 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-23380
original_published: 2022-10-27 00:00:00 +0000
significance: 8.00
---

# Quantitative Brain Amyloid Positron Emission Tomography Imaging in Patients With Alzheimer's Disease; Public Workshop; Request for Comments

**Published:** February 05, 2026 19:01 UTC
**Source:** Federal Register
**Original Published:** October 27, 2022 00:00 UTC
**Document Number:** 2022-23380

## Summary

The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public workshop entitled "Quantitative Brain Amyloid PET Imaging in Patients with Alzheimer's Disease." The purpose of the public workshop is to evaluate the role of quantitative positron emission tomography (PET) measures of amyloid deposition in the brain in clinical trials and clinical use in patients with suspected or confirmed Alzheimer's disease.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/10/27/2022-23380/quantitative-brain-amyloid-positron-emission-tomography-imaging-in-patients-with-alzheimers-disease)
- API: https://www.federalregister.gov/api/v1/documents/2022-23380

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
